Keywords: Multiple sclerosis, Oral therapes, Russia, Datamonitor, Merck Serono, Movectro, Novartis, Gilenia

A new era of multiple sclerosis therapies begins as oral drugs come to market

Article | 15 July 2010

Print This

New and improved multiple sclerosis (MS) drugs satisfying key unmet needs of oral administration and increased efficacy suggest a paradigm ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in